GlassScriptPhysician profile
Jillian Savage
NPI 1194267450
$1,908.07
in general payments reported to CMS, 2019-2025
15 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.24 · 2022: $251 · 2023: $303 · 2024: $864 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $690 · Food and Beverage: $665 · Consulting Fee: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $689.99 |
| Food and Beverage | $665.37 |
| Consulting Fee | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $444.40 | 2023-2024 | Erleada, Rybrevant, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $336.96 | 2023-2024 | Lynparza, Imfinzi |
| Seagen INC. | $293.95 | 2022-2025 | |
| Astellas Pharma US INC | $233.40 | 2025 | Padcev |
| Daiichi Sankyo INC. | $201.54 | 2022-2025 | Enhertu |
| Incyte Corporation | $136.27 | 2024-2025 | Opzelura |
| Abbvie INC. | $61.74 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.79 | 2024 | Ninlaro |
| Genzyme Corporation | $30.02 | 2022 | |
| Gilead Sciences, INC. | $29.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.93 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $23.27 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Morphosys, US INC. | $21.24 | 2021 | |
| Springworks Therapeutics, INC. | $18.16 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.